European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): protocol for an international, prospective registry study.
Daria Chernysheva, Stefano Fanti, Anders Bjartell...
https://pubmed.ncbi.nlm.nih.gov/41338644/Actively Recruiting
Led by Fundacio Puigvert · Updated on 2025-03-11
600
Participants Needed
24
Research Sites
52 weeks
Total Duration
Researchers are collecting real-world data on advanced prostate cancer to evaluate the role of next-generation imaging NGI, such as PETCT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. This study focuses on men aged 18 or older with confirmed prostate cancer who need imaging to assess possible metastases either at diagnosis or after relapse. It aims to understand when NGI should be used, how it influences treatment decisions, and its impact on patient outcomes. Participants will receive standard care without experimental treatments. Imaging will be done using either conventional methods, NGI, or both, according to local clinical practice and guidelines. The study includes a cross-sectional observation to evaluate imaging benefits and a longitudinal observation to assess survival outcomes and treatment response based on the imaging approach used. During the study, data will be collected from medical records including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will track the proportion of patients requiring each imaging type and changes in treatment prompted by imaging results within 4 to 6 weeks. The study involves no additional procedures beyond routine care, and participation will continue until the study end in December 2026.
CONDITIONS
European Registry of Next Generation Imaging in Advanced Prostate Cancer
F
Francesco Sanguedolce, MD, PhD
D
Daria Chernysheva, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundacio Puigvert
Lead Sponsor
European Association of Urology Research Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 to 6 weeks
Participants undergo imaging exploration using conventional imaging, next generation imaging, or both to assess metastatic prostate cancer.
1 to 2 imaging visits depending on imaging modality
Duration - Up to several years
Participants are observed over time to evaluate survival outcomes and disease progression in relation to the imaging pathway undertaken.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Daria Chernysheva, Stefano Fanti, Anders Bjartell...
https://pubmed.ncbi.nlm.nih.gov/41338644/Fundacio Puigvert
Lead Sponsor
European Association of Urology Research Foundation
Collaborating Sponsor